get a key
steadybase-$ company COCH
account_id none on file
legal_name Envoy Medical, Inc.
ticker COCH
cik 1840877
domain envoymedical.com
linkedin_company_url none on file
entry_point_account_id none on file
name Envoy Medical Inc.
exchange Nasdaq
sector Health Care
calls 0 filings 14 executives 1 family 0
why_nownone on file
callsnone on file
filings
This process, which is commonly referred to as “householding,” potentially means extra convenience for stockholders and cost savings for companies.

filing / Aug 31, 2026 / receipt

This process, which is commonly referred to as “householding,” potentially means extra convenience for stockholders and cost savings for companies.

filing / Aug 31, 2026 / receipt

travel expenses engaged in R&D functions; ● costs of laboratory testing including supplies and acquiring, developing, and manufacturing study materials; and ● facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.

filing / Aug 10, 2026 / receipt

These increases will likely include the hiring of additional personnel and legal, regulatory, and other fees and services associated with maintaining compliance with Nasdaq and SEC requirements, director and officer costs, including insurance, and investor relations costs associated with being a public company.

filing / Aug 10, 2026 / receipt

occur such that we do not meet our strategic plans, we may be required to reduce certain discretionary spending, be unable to develop

filing / Aug 10, 2026 / receipt

If we are unable to raise capital, we will need to delay, reduce, or terminate planned activities to reduce costs. Macroeconomic Conditions Our business and financial performance are impacted by macroeconomic conditions.

filing / Aug 10, 2026 / receipt

consist of our operating leases for office space and a litigation matter arising from the Company’s Business Combination.

filing / Aug 10, 2026 / receipt

historically consist of receiving term loan financings which have been extinguished, leasing our headquarters office space, and contracting

filing / Aug 10, 2026 / receipt

travel expenses engaged in R&D functions; ● costs of laboratory testing including supplies and acquiring, developing, and manufacturing study materials; and ● facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.

filing / Aug 10, 2026 / receipt

These increases will likely include the hiring of additional personnel and legal, regulatory, and other fees and services associated with maintaining compliance with Nasdaq and SEC requirements, director and officer costs, including insurance, and investor relations costs associated with being a public company.

filing / Aug 10, 2026 / receipt

occur such that we do not meet our strategic plans, we may be required to reduce certain discretionary spending, be unable to develop

filing / Aug 10, 2026 / receipt

If we are unable to raise capital, we will need to delay, reduce, or terminate planned activities to reduce costs. Macroeconomic Conditions Our business and financial performance are impacted by macroeconomic conditions.

filing / Aug 10, 2026 / receipt

executives
Robert Potashnick Interim Chief Financial Officer - receipt
familynone on file
upcoming
2026-11-09 earnings call scheduled ir
changes
2025-06-25 Interim Chief Financial Officer, appointed sec_8k
2023-10-05 director, departed sec_8k
2022-08-04 Chief Financial Officer, departed sec_8k
mcp_package_hint
steadybase-$